11 Best Fast Money Stocks To Buy Now

6. Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)

Upside Potential as of September 29, 2025: 117.07%

During the second quarter, Pallas Capital Advisors acquired a new position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) through the purchase of 13,182 shares of the company’s stock. According to the latest filing with the SEC, the firm’s investment in the company is approximately $59,000.

There are many advocates for Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), and it comes as no surprise. The company has managed to strike another deal with Novartis, which involves both companies developing molecular glue degraders for immune-mediated disorders. This is yet another major highlight as it brings forth $120 million in proceeds, along with the potential to generate $5.7 billion in milestone payments.

If that weren’t already a strong case, Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) has been awarded IND clearance from the FDA to accelerate MRT-8102, a second molecular glue degrader. As long as the company executes its initiatives successfully, we have a good reason to believe in the potential for this stock to be rewarding.

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) is a Massachusetts-based clinical-stage biotechnology company developing novel small-molecule precision medicines. Incepted in 2019, the company maintains a strategic partnership and licensing agreement with F. Hoffmann-La Roche Ltd.